Part of Thermo Fisher Scientific

Proteomics in drug development

Protein biomarker studies accelerate drug discovery and development. They can increase the probability of successfully implementing new therapies by enabling deep knowledge of the biology underlying human disease and providing actionable insights to guide key decision-making.

Illustration: Ibrahim Rayintakath

Addressing key challenges

Escalating costs and increasing demands from regulatory authorities for a more precision medicine-based approach to drug development are substantial challenges for the pharmaceutical industry. Olink’s PEA technology is increasingly used to identify new drug targets and analyze samples from clinical trials to stratify patient populations, predict responses, and provide insights into the biology of disease and drug modes of action.

Selected interview

Dr. Chris Whelan (Chair and Principal Investigator of the UK Biobank – Pharma Proteomics Project) discusses how data from the UK Biobank – Pharma Proteomics Project has revealed new insights into associations between gene variants and protein concentrations enabling new causal biomarkers for diseases to be identified as well as new drug targets with higher probabilities of success.

Working with Olink

See what some leading scientists in their fields have to say about their experiences working with Olink and our PEA solutions for drug development.

Proteomics helps provide a much needed layer of resolution to genetic data. Genomics is the beautiful, reliable but slightly ageing car – proteomics might serve as the new engine

Dr. Chris Whelan, Chair and Principal Investigator of the UK Biobank – Pharma Proteomics Project

Our work with Olink on plasma-based immuno-oncology (IO) applications has allowed the identification of tumor and immune changes associated with immune checkpoint inhibitor response/non-response. This is particularly exciting as we combine this technology with deep tumor-based analysis to understand tumor-immune interactions and establish predictive and/or monitoring tools for IO. The small volume required for Olink analysis is a game-changer as it allows multi-analyte assessment of samples and validation of findings by multiple orthogonal platforms.

Genevieve M. Boland, Director Melanoma Surgery Program, Massachusetts General Hospital, Boston

My interest in biomarkers grew in parallel to the growth of Olink. In 2014, when I first selected the Olink technology for an important EU-funded program I was coordinating, the company had only a handful of employees. Since then, Olink’s growth has been amazing. Yet, they still behave like partners, not simple providers. I have since recommended Olink to many international colleagues.

Prof. Faiez Zannad, Therapeutics and Cardiology at INSERM, Head of the Division of Heart Failure, Hypertension and Preventive Cardiology for the Department of Cardiovascular Disease of the Academic Hospital (CHU) in Nancy and the Director of the Clinical Investigation Centre (Inserm-CHU)

Selected reading

Olink’s PEA technology is advancing drug repurposing efforts. Studies highlight its role in identifying biomarkers for heart failure (EMPEROR study), predicting rheumatoid arthritis treatment responses, and enabling early cancer detection and patient stratification, enhancing drug development and precision medicine.

A flexible platform that accelerates your research

Olink’s scalable technology provides optimized solutions for every stage of the biomarker workflow, from high-throughput discovery through validation and clinical utility.

Get help choosing. Talk to a Specialist

Olink Explore HT

Measure 5,400+ proteins with proven specificity to gain an understanding of disease at the protein level.


5,400+ With proven specificity


2 µL Plasma, serum & more

Olink Flex

Run individually tailored studies by combining up to 21 biomarkers from our extensive library with minimal sample volume.


~200 Pre-validated assays


1 µL Plasma, serum & more

Olink Target 96

Target specific disease areas or key biological processes with multiplex immunoassay panels.


1,100+ On 15 targeted panels


1 µL Plasma, serum & more

Olink Target 48

Extensively validated and carefully selected biomarkers for a comprehensive view of cytokine signaling and inflammatory processes.


89 On 2 panels


1 µL Plasma, serum & more